Drug Profile
Research programme: antisense oligonucleotides - ARC Pharmaceuticals
Latest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator McGill University
- Developer ARC Pharmaceuticals; McGill University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 19 Aug 2002 Preclinical trials in Cancer in Canada (unspecified route)